Krónikus limfoid leukémia (CLL): vizsgálatok itt: Németország
37 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Where
- Frankfurt Am Main, Mainz, Munich
- Életkor
- 18 év and over
- People
- 306 worldwide
- Run by
- Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00 - 1. fázisTaking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00 - 3. fázisTaking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Leipzig, Trier, Ulm
- Életkor
- 18 év and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Augsburg, Cologne, Ulm
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Cologne, Frankfurt, Göttingen, Hannover, Hoesbach, Koblenz, Muenster
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - 1/2. fázisTaking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Cologne, Homburg, Kiel, Mainz, Munich, Wuerzburg
- Életkor
- 18 év and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Cologne, Dresden, Siegen, Ulm
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Berlin, Cologne, Dresden, Jena, Kiel, Munich, Mutlangen, Neubrandenburg, Tuebingen, Ulm, Wuerzburg
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - No phaseTaking peopleStudy of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
- Where
- Aschaffenburg, Augsburg, Baden-Baden, Bad Liebenwerda, Bad Mergentheim, Bad Reichenhall, Berlin, Bremerhaven, Cologne, Deggendorf, Dresden, Eisenach, Erlangen, Frankfurt am Main, Frankfurt (Oder), Freiburg im Breisgau, Goslar, Hagen, Halle, Hamburg, Hamm, Hanau, Hanover, Hof, Idar-Oberstein, Kaiserslautern, Kassel, Kronach, Landshut, Langenhessen, Lübeck, Magdeburg, Munich, Mutlangen, Neumünster, Neunkirchen, Neuss, Oldenburg, Osnabrück, Paderborn, Porta Westfalica, Potsdam, Regensburg, Rostock, Schwäbisch Hall, Schwetzingen, Stuttgart, Villingen-Schwenningen, Westerstede
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- AbbVie
See details and how to joinNCT03342144 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Giessen, Mainz
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisTaking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Berlin, Halle (Saale), Koblenz, Landshut, Moenchengladbach, Ulm
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - 1/2. fázisTaking peopleLong-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
- Where
- Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, Wuerzburg
- People
- 40
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT06508775 · EU 2022-501648-14-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 1/2. fázisTaking peopleVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- Where
- Cologne, Freiburg im Breisgau, Halle (Saale), Kiel, Muenster, Stuttgart, Ulm
- Életkor
- 18 év and over
- People
- 112 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT05791409 · EU 2022-500305-40-00 - 3. fázisTaking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Aachen, Amberg, Berlin, Bonn, Chemnitz, Cologne, Dortmund, Dresden, Duesseldorf, Essen, Esslingen am Neckar, Frankfurt Am Main, Frechen, Freiburg im Breisgau, Hamburg, Hamm, Hannover, Heidelberg, Herne, Hildesheim, Homburg, Jena, Kaiserslautern, Karlsruhe, Kiel, Leipzig, Mannheim, Munich, Mutlangen, Paderborn, Ravensburg, Regensburg, Rostock, Siegburg, Stuttgart, Tuebingen, Ulm, Weiden I D Opf, Wuerzburg
- Életkor
- 18 év and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00 - 4. fázisTaking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00 - 1/2. fázisTaking peopleQUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers
- Where
- Berlin, Dresden, Erlangen, Essen, Hamburg, Marburg, Munich, Ulm
- Életkor
- 18 év and over
- People
- 60
- Run by
- Avencell Therapeutics Inc.
See details and how to join2025-521735-36-00 · EU 2025-521735-36-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Göttingen, München, Ulm, Würzburg
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - 3. fázisTaking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Augsburg, Berlin, Chemnitz, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Homburg, Koblenz, Leipzig, Muenster
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm, Westerstede
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Deggendorf, Frankfurt am Main, Koblenz, Muenster, Osnabrueck, Straubing
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - No phaseTaking peopleZanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- Where
- Lübeck
- Életkor
- 18 év and over
- People
- 845 worldwide
- Run by
- iOMEDICO AG
See details and how to joinNCT05326308 - 3. fázisTaking peopleA Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Where
- Bad Saarow, Berlin, Bremen, Cologne, Dortmund, Düsseldorf, Eschweiler, Essen, Hagen, Homburg, Idar-Oberstein, Karlsruhe, Kiel, Landshut, Lemgo, Limburg, Magdeburg, Meschede, Mönchengladbach, Munich, Mutlangen, Oldenburg, Paderborn, Rostock, Saarbrücken, Sindelfingen, Stuttgart, Tübingen, Ulm
- Életkor
- 18 év to 120 év
- People
- 202
- Run by
- German CLL Study Group
See details and how to joinNCT05197192 · EU 2023-506414-46-00 - 3. fázisTaking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Dresden, Ulm
- Életkor
- 18 év and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - 1. fázisTaking peopleStudy Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Augsburg, Ulm
- Életkor
- 18 év and over
- People
- 54 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2022-501876-24-00 · EU 2022-501876-24-00